Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065596 · ClinicalTrials.gov registry record · Phase 1
Hematopoietic Stem Cell Transplant for Sickle Cell Disease
A Phase 1 study of Sickle Cell Disease and Sickle Cell Anemia, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT02065596 is a Phase 1 study of Sickle Cell Disease and Sickle Cell Anemia that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 4 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02065596, a Phase 1 study of Sickle Cell Disease and Sickle Cell Anemia, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study of patients with sickle cell disease. It aims to find out if people with sickle cell disease can be cured by changing their immune system before they have blood stem cell transplants. Doctors will give patients a new drug (fludarabine) to see if this drug changes patients immune system and reduces the patient's cells (host) from rejecting donor cells (graft) after the patient gets a Hematopoietic (blood) stem cell transplant.
Conditions Studied
Interventions
- DRUG Fludarabine
- PROCEDURE Hematopoietic Stem Cell Transplant (HSCT)
Study Locations (1)
Ohio
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-10-19 |
| Est. Completion | 2023-02-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02065596
The ClinicalTrials.gov registry entry for NCT02065596 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (99% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Fludarabine is the first listed.
NCT02065596 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02065596 about?
NCT02065596 is a clinical study titled "Hematopoietic Stem Cell Transplant for Sickle Cell Disease". This is a study of patients with sickle cell disease. It aims to find out if people with sickle cell disease can be cured by changing their immune system before they have blood stem cell transplants. Doctors will give patients a new drug (fludarabine) to see if this drug changes patients immune syst...
What is the current status of trial NCT02065596?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-10-19. Estimated completion is 2023-02-17.
What conditions does trial NCT02065596 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Sickle Cell Anemia, SCD.
What interventions are being tested in trial NCT02065596?
The interventions under investigation include: Fludarabine (DRUG), Hematopoietic Stem Cell Transplant (HSCT) (PROCEDURE).
Who is sponsoring clinical trial NCT02065596?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02065596 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.